Genflow Biosciences Raises £440,000 Through Alternative Share Placement.
Genflow Biosciences Plc announced that it has terminated the previously announced transaction from October 2, 2025, and instead completed an alternative fundraising, raising £440,000 before expenses.
The funding was secured through the allotment of 40,000,000 new ordinary shares at 1.1 pence per share to Eric Leire. Of these, 35,454,546 shares will be transferred to a consortium of existing shareholders, with Leire retaining 4,545,454 shares.
Both the purchasers and Leire will receive warrants on a one-for-one basis, exercisable at 1.2 pence per share for 24 months.
Following admission, the company’s issued share capital and voting rights will total 493,547,942 ordinary shares. Admission to the FCA Official List and trading on the London Stock Exchange is expected at around 8:00 a.m. on October 16, 2025.
Dr. Eric Leire, CEO of Genflow, commented: “We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow’s vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives.”
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow’s 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
